Xcell Biosciences is developing novel and disruptive systems for cell therapy development and production. Demand for new immune cell therapies, such as CAR-T, has far outpaced the tools to develop and validate them. Current methods of evaluating therapeutic potential lack physiologically relevant readouts. This has resulted in a large predictive gap between preclinical insights and actual clinical results. There is a large unmet need to model primary immune and tumor cell functional interactions under a tumor microenvironment in order to ensure optimal efficacy and persistence in vivo. Furthermore, these insight must be taken into a manufacturing context or performance gains may be lost to cell exhaustion or loss of phenotype during culture.
Our solutions focus on clinical researchers developing therapies at the convergence of precision medicine, stem cell technology, and immunotherapy. Our proprietary technology, unlike traditional cell biology technologies, combines rapid primary cell expansion and fine control of cell population mix and phenotype across a range of therapeutically important human cell types. We are using this unique cell control system to work with immunotherapy partners to offer tailored solutions for immunotherapy performance optimization and to optimize cell therapy manufacturing workflows.